Malaria caused by *Plasmodium falciparum* parasites remains one of the most significant global public health challenges, with more than 200 million cases and 438,000 deaths in 2015 ([@r1]). There has recently been significant progress in reducing malaria mortality ([@r2]), but the emergence and spread of parasites resistant to current frontline antimalarial artemisinin ([@r3]) threaten current control methods and emphasize the need for novel control and intervention tools, such as an effective vaccine. Malaria vaccine development has been challenging, with only one vaccine, RTS,S (Mosquirix), reaching phase III trials, where it had limited, albeit consistent, efficacy ([@r4]). While the WHO has recommended that RTS,S be advanced to large-scale pilots in Africa, the well-established partial efficacy coupled with concerns about strain-specific responses ([@r5]) makes identifying additional components to include in a second-generation *P. falciparum* vaccine an urgent priority.

Two significant challenges confront *P. falciparum* antigen identification---the complexity of the parasite life cycle, which presents a large number of potential targets, and the depth of genomic diversity across global parasite populations ([@r6]), which makes the development of strain-transcending protection difficult. Given these twin challenges, an effective second-generation vaccine will almost certainly need to target multiple components simultaneously ([@r7]). Despite this fact, malaria vaccine development has so far primarily focused on a very limited number of targets, leaving the vast majority of potential candidates encoded by the \>5,000-gene *P. falciparum* genome unexplored ([@r8]). The search for vaccines targeting erythrocyte invasion is a microcosm of this broader challenge. Erythrocyte invasion, the process by which *P. falciparum* merozoites recognize, form protein--protein interactions with, and then actively invade human erythrocytes, is essential for parasite survival and is the only window during blood stage development when the parasite is extracellular and therefore exposed to antibody-mediated inhibition. It is also a very complex process, potentially involving more than 400 genes, including more than 100 that may encode for surface-exposed proteins ([@r9]). Until now, however, invasion-blocking vaccines have focused on only a handful of targets, which not coincidentally were also among the first *P. falciparum* genes ever sequenced ([@r8]).

A reverse vaccinology approach will be needed to identify new targets from this long candidate list, incorporating systematic screens of a larger number of antigens and using data from multiple sources to identify potentially synergistic combinations. We have previously used a mammalian expression system to express a library of entire ectodomains, up to 200 kDa in length, from merozoite-expressed *Plasmodium* proteins that are thought to be involved in erythrocyte recognition and entry ([@r10]). Expressing full-length protein ectodomains in the context of a eukaryotic secretory pathway allows disulphide bonds to form and maximizes the chance that the recombinant antigens will fold correctly to mimic the function and antigenicity of native *P. falciparum* proteins, all of which pass through the *P. falciparum* secretory pathway. This library has been used to identify new protein--protein interactions ([@r11]), perform detailed biochemical analysis of known interactions ([@r12]), and underpin large-scale immunoepidemiological studies to identify targets of protective immunity ([@r13]). In this study, we tested whether this ectodomain library could be used to identify new erythrocyte invasion-blocking vaccine combinations by raising antibodies against multiple *P. falciparum* proteins, systematically testing their ability to inhibit invasion, and incorporating immunoepidemiological and mechanistic data to identify synergistic combinations.

Results {#s1}
=======

Systematic Screening Identifies Strain-Transcendent Vaccine Candidates. {#s2}
-----------------------------------------------------------------------

The extracellular domain of each target protein, based on the sequence from the ref. 3D7 *P. falciparum* genome, was produced in a soluble recombinant form by transient transfection of HEK239E cells ([@r14]). We down-selected 29 targets for further investigation, based both on the diversity of their known or inferred subcellular location and on pragmatic considerations such as protein expression level ([Fig. S1](#sfig01){ref-type="fig"} and [Table S1](#st01){ref-type="table"}). We purified 0.4--1.0 mg of each protein using nickel affinity chromatography and used them to raise polyclonal rabbit antibodies. Total IgG antibodies were purified using protein G columns and tested by ELISA to confirm binding activity against the immunizing antigens ([Fig. S2](#sfig02){ref-type="fig"}) before being used in growth inhibition activity (GIA) assays.

![Antigen quality assessment by SDS/PAGE. Composite image of reducing SDS/PAGE gels shows samples of each recombinant ectodomain antigen (1 µg, determined by absorbance at 285 nm), after nickel column purification, arranged in order of descending predicted molecular weight. In most cases, the low expression level of the antigen necessitated processing of large volumes of tissue culture supernatant; this resulted in the retention of nonspecfic proteins, such as serum albumin. The presence of the desired antigen in each purified sample was determined by ELISA using tag-specific antibodies before immunization. M, protein markers.](pnas.1702944114sfig01){#sfig01}

###### 

Expression levels of recombinant *P. falciparum* ectodomains and purified antibody titers

  Antigen      Expression level of antigen, nmoles protein/L transfection supernatant   Purified antibody titer, µg/mL   Maximum IgG GIA dose, mg/mL
  ------------ ------------------------------------------------------------------------ -------------------------------- -----------------------------
  MSP2         270.0                                                                    0.7                              6.6
  MSRP1        197.9                                                                    0.5                              5.9
  RON12        134.5                                                                    0.4                              5.0
  MSRP4        124.4                                                                    2                                4.5
  Pf34         120.8                                                                    1.5                              4.7
  AARP         118.4                                                                    0.9                              6.8
  RON6         97.6                                                                     1                                6.4
  MSP3         72.0                                                                     0.15                             4.6
  ASP          68.8                                                                     0.4                              4.5
  MSRP2        35.8                                                                     0.6                              5.4
  H101         29.4                                                                     0.7                              5.3
  SPATR        23.1                                                                     0.15                             5.3
  MSRP5        22.4                                                                     3                                5.1
  ETRAMP10.2   18.9                                                                     1.3                              6.3
  PFA0135w     16.9                                                                     0.5                              5.6
  MSP1         16.0                                                                     0.4                              4.5
  PF11_0373    15.7                                                                     0.15                             6.3
  MSP10        10.0                                                                     0.05                             6.0
  PTEX150      6.6                                                                      0.7                              6.7
  SERA4        6.5                                                                      0.5                              4.6
  RAMA         4.6                                                                      0.5                              5.4
  PFF0335c     3.9                                                                      0.6                              5.9
  PF10_0351    3.9                                                                      2.2                              4.0
  CyRPA        3.1                                                                      0.6                              3.9
  RhopH3       2.6                                                                      1                                5.2
  SERA9        2.3                                                                      0.08                             3.9
  EBA181       2.1                                                                      1.5                              4.8
  EBA140       2.0                                                                      0.6                              3.8
  TLP          1.2                                                                      0.5                              4.1

![Antigen expression and corresponding antibody titers. Graphs show the expression level (nanomoles purified protein per liter transfection supernatant) of each antigen produced at a large scale (black bars) and the titer (micrograms per milliliter, *y* axis) of the corresponding purified, polyclonal antibodies raised against them, determined by ELISA (gray bars).](pnas.1702944114sfig02){#sfig02}

To establish whether each antibody alone could inhibit parasite growth, late trophozoite stage *P. falciparum* parasites were cultured in the presence of IgG at the maximum concentration that could be purified from the polyclonal antisera. Parasites were incubated with each IgG for 24 h to allow sufficient time for erythrocyte invasion to occur, before parasitemia was measured using flow cytometry ([@r15]). Antigen polymorphism has been a major cause of failure for previous *P. falciparum* candidate antigens. To incorporate testing for strain-transcending inhibition at the earliest stage of candidate down-selection, antibodies against all 29 targets were tested against both 3D7 and Dd2 parasites, which have genome sequences broadly representative of West African and Asian *P. falciparum* parasites, respectively, and differ at \>15,000 nucleotide positions across the 23-Mb genome ([@r16]). IgG purified from polyclonal antibodies raised against PfRh5, a leading strain-transcending blood-stage vaccine candidate ([@r17], [@r18]), was used as a comparator in this and subsequent experiments. Antibodies raised against the 3D7 variants of PfMSP1, PfSERA9, PfMSRP5, PfEBA181, PfCyRPA, and PfRAMA all had a strong inhibitory effect on the growth of both 3D7 and Dd2 parasites, inhibiting 3D7 growth to a similar extent as anti-PfRh5 antibodies ([Fig. 1](#fig01){ref-type="fig"}). PfEBA181, PfMSRP5, and PfSERA9 are members of gene families in which at least one other gene is known or suspected to play a role in erythrocyte invasion \[PfMSP7-like ([@r19]), EBL ([@r20]), PfSERA ([@r21])\], so the inhibitory effects of each of these antibodies could in part be explained by cross-reactivity against multiple members of each protein family. We therefore tested the ability of the purified IgG for each of these proteins to recognize other members of each family, but only in the case of PfMSRP5-specific IgG was there any evidence for cross-reactivity ([Fig. S3](#sfig03){ref-type="fig"}), suggesting the IgG responses are largely target-specific. PfCyRPA is a member of a protein complex that includes PfRh5 ([@r22], [@r23]), while little is known about the function of PfRAMA, although antibodies against it have previously been associated with protection against malaria ([@r24]). PfMSP1 is an extensively studied vaccine target with known allele-specific effects ([@r25]) and so was excluded from further study.

![Systematic screening of antibodies to *P. falciparum* antigens for cross-strain activity. The 3D7 (black bars) and Dd2 (gray bars) strains of *P. falciparum* were grown for 48 h in in vitro culture in the presence of purified rabbit polyclonal IgG raised against members of a panel of recombinant merozoite protein ectodomains. Bars represent mean growth relative to positive control wells lacking antibodies, and error bars represent SD (*n* = 3). Merozoite ectodomains are grouped by their known or predicted subcellular location.](pnas.1702944114fig01){#fig01}

![Limited cross-reactivity of anti-PfMSRP5 polyclonal antibodies with PfMSP7. Representative ELISA results using purified polyclonal antibodies (100 µg/mL) raised against (*A*) PfEBA181, (*B*) PfMSRP5, or (*C*) PfSERA9 to detect cross-reactivity with other members of the EBA, MSP7, or SERA families, respectively. The antibodies were tested with (black bars) or without (gray bars) depletion of activity against the tag fused to each recombinant protein immobilized on the microtiter plates (compare black and gray bars marked in *A*--*C*). These results show limited cross-reactivity of anti-PfMSRP5 antibodies to PfMSP7 and no detectable cross-reactivity of anti-PfSERA9 or anti-PfEBA181 antibodies. Average absorbance at 405 nm (*n* = 3); error bars represent SD.](pnas.1702944114sfig03){#sfig03}

To quantitatively compare the inhibitory potential of IgG specific for the remaining five targets, GIA assays were performed using increasing concentrations of purified IgG to generate IC~50~ values. All exhibited a clear dose-dependent inhibitory effect on the growth of both 3D7 and Dd2 parasites ([Fig. S4](#sfig04){ref-type="fig"}), with IC~50~ values ranging from 0.25 mg/mL to 1.5 mg/mL total IgG ([Table S2](#st02){ref-type="table"}). Antibodies raised against PfSERA9, PfMSRP5, and PfRh5 did not show any evidence of strain specificity, with almost no difference in IC~50~ values between the two strains. Antibodies against PfEBA181, PfCyRPA, and PfRAMA all showed some reduction in efficacy against Dd2 relative to 3D7 parasites, with an accompanying 1.7-fold (PfCyRPA and PfRAMA) and 2.7-fold (PfEBA181) increase in IC~50~ values. However, the difference in IC~50~ values for PfCyRPA and PfRAMA against 3D7 and Dd2 parasites was relatively minor and of a similar magnitude to shifts in IC~50~ values between different strains for anti-PfRh5 antibodies ([@r18]), and moreover, PfCyRPA has previously been reported to have broadly strain-transcendent effects ([@r22], [@r26]). Strain specificity is therefore only an immediate concern in the case of PfEBA181.

![Strong, strain-transcending dose-dependent inhibition of growth by antibodies raised against five blood-stage vaccine candidates. Graphs show results of growth inhibition assays performed using either 3D7 (open circles) or Dd2 (black circles) strains and with increasing concentration of anti-PfSERA9 (*A*), anti-PfMSRP5 (*B*), anti-PfEBA181 (*C*), anti-PfCyRPA (*D*), or anti-PfRAMA (*E*) purified polyclonal antibodies added to the culture media. Both strains of parasite were strongly inhibited by all six polyclonal antibodies, although a small difference in efficacy was observed for anti-PfEBA181, anti-PfCyRPA, and anti-PfRAMA. Circles represent mean values (*n* = 3); error bars represent SE. Lack of strain specificity for anti-PfRh5 has been reported previously by multiple groups ([@r3], [@r14], [@r15]), and anti-PfCyRPA has also previously shown to have a strain-transcending protective effect ([@r4], [@r19]). By contrast, antibodies against stain-specific targets such as AMA1 have clear differences in efficacy between strains ([@r15]).](pnas.1702944114sfig04){#sfig04}

###### 

IC~50~ values in 3D7 and Dd2

  Antigen    IC~50~, μg/mL   
  ---------- --------------- ---------
  PfSERA9    247.0           288.0
  PfMSRP5    989.2           1,021.0
  PfEBA181   555.4           1,544.0
  PfCyRPA    384.8           653.0
  PfRAMA     707.9           1,174.0
  PfRH5      856.5           710.4

Candidates Identified in Vitro Are Associated with Protection from Clinical Malaria in Vivo. {#s3}
--------------------------------------------------------------------------------------------

Repeated exposure to *P. falciparum* malaria generates immune responses to a large number of antigens ([@r13], [@r27]), which can result in clinical immunity. To investigate whether antibodies to these vaccine targets contribute to clinical immunity, we tested for the presence of naturally acquired IgG in uninfected Malian individuals enrolled in a prospective cohort study in which we previously described an association between PfRh5-specific IgG and protection from febrile malaria ([@r28]). At the uninfected baseline before the 6-mo malaria season, antigen-specific IgG levels and seroprevalence increased with age for all antigens except for PfCyRPA, which demonstrated poor natural immunogenicity, similar to its binding partner PfRh5 ([Fig. 2 *A* and *B*](#fig02){ref-type="fig"}). We next evaluated whether these baseline IgG levels predicted protection from febrile malaria during the ensuing malaria season. Associations between risk of febrile malaria, as measured by time-to-first febrile malaria episode after incident blood-stage infection, and IgG levels for each antigen, alone and in combination, were examined using a Cox regression model that included age, sickle cell trait, gender, and anemia as covariates. Although IgG specific for PfCyRPA, PfEBA181, PfMSRP5, PfRAMA, or PfSERA9 did not predict protection individually, the combined presence of IgG specific for PfEBA181, PfMSRP5, or PfRAMA with PfRh5-specific IgG was associated with reduced malaria risk relative to PfRh5-specific IgG alone, albeit with overlapping confidence intervals (CIs) ([Table S3](#st03){ref-type="table"}). A significantly reduced hazard ratio for the anti-PfEBA181 IgG + anti-PfRH5 IgG combination relative to anti-PfEBA181 IgG alone suggests that antibodies generated against these two antigens may provide malaria-protective synergy ([Table S3](#st03){ref-type="table"}). Notably, two combinations that did not contain anti-PfRh5 IgG (anti-PfEBA181 IgG + anti-PfMSRP5 IgG + anti-PfRAMA IgG and anti-PfMSRP5 IgG + anti-PfRAMA IgG) also predicted protection from malaria ([Table S3](#st03){ref-type="table"}). The protective effect of anti-PfEBA181 IgG + anti-PfMSRP5 IgG + anti-PfRAMA IgG, but not PfMSRP5 IgG + anti-PfRAMA IgG, remained significant even after controlling for reactivity against other *P. falciparum* antigens, including PfRh5 ([Fig. 2*C*](#fig02){ref-type="fig"}). To determine whether positive IgG responses affected parasite growth, we compared in vivo parasite multiplication rates (PMRs) between negative and positive responders for each antigen combination among individuals for whom parasite density data were available. Although IgG responses to PfMSRP5 + PfRh5 and PfRAMA associated with lower PMRs in univariate analyses, these associations were not significant after adjusting for multiple testing or in logistic regression models that included age, sickle cell trait, anemia, and gender as covariates ([Table S4](#st04){ref-type="table"}).

![Antigens are targets of natural IgG responses that are associated with protection from malaria in specific combinations. (*A*) IgG reactivity against PfCyRPA, PfEBA181, PfMSRP5, PfRAMA, or PfSERA9 in plasma samples from 351 Malians across age groups. Shown is background-subtracted optical density (OD 450 nm) by ELISA. Boxes enclose interquartile range, central lines represent medians, whiskers indicate the 5--95 percentile, and dots are outliers. (*B*) Seroprevalence of IgG with AUs of \>1 against all antigens across age groups. "AU of 1" is defined as the mean OD value plus 3 SDs for 24 malaria-naïve US donors. (*C*) A Cox regression model was used to evaluate the effect of different combinations of antigen-specific IgG responses on the risk of the first febrile malaria episode of the season using time of first PCR-detectable *P. falciparum* blood-stage infection as the start time for febrile malaria risk analysis. Shown are forest plots for the most significant combinations that did not include PfRh5.](pnas.1702944114fig02){#fig02}

###### 

Output of Cox regression model for all antigen combinations

  Antigen combination                                       Sample size   Events   Hazard ratio   Lower 95% CI   Upper 95% CI   Cox model *P* value   Cox BH-adjusted *P* value   ZPH *P* value   Global ZPH *P* value
  --------------------------------------------------------- ------------- -------- -------------- -------------- -------------- --------------------- --------------------------- --------------- ----------------------
  PfEBA181 + PfRH5                                          277           191      0.3240         0.1752         0.5991         0.0003                0.0206                      0.7851          0.3084
  PfEBA181 + PfRAMA + PfRH5                                 277           191      0.2167         0.0756         0.6209         0.0044                0.2691                      0.7497          0.2551
  PfEBA181 + PfMSRP5 + PfRAMA + PfRH5                       277           191      0.2167         0.0756         0.6209         0.0044                0.2691                      0.7497          0.2551
  PfEBA181 + PfSERA9 + PfRH5                                277           191      0.3735         0.1858         0.7508         0.0057                0.3421                      0.9285          0.3081
  PfEBA181 + PfMSRP5 + PfRH5                                277           191      0.3262         0.1450         0.7339         0.0068                0.3998                      0.6043          0.2589
  PfMSRP5 + PfRAMA + PfRH5                                  277           191      0.2761         0.1063         0.7169         0.0082                0.4756                      0.7238          0.2737
  PfRAMA + PfRH5                                            276           191      0.2795         0.1077         0.7253         0.0088                0.5013                      0.7189          0.2821
  PfEBA181 + PfMSRP5 + PfRAMA                               277           191      0.4329         0.2310         0.8115         0.0090                0.5045                      0.9215          0.2569
  PfMSRP5 + PfRH5                                           276           191      0.4064         0.2049         0.8062         0.0100                0.5494                      0.5335          0.2268
  PfMSRP5 + PfRAMA                                          277           191      0.4904         0.2742         0.8773         0.0163                0.8828                      0.9782          0.2833
  PfRH5                                                     273           189      0.5862         0.3763         0.9134         0.0183                0.9684                      0.3697          0.2768
  PfRAMA + PfSERA9 + PfRH5                                  277           191      0.3265         0.1152         0.9259         0.0353                0.9996                      0.6314          0.2652
  PfEBA181 + PfRAMA + PfSERA9 + PfRH5                       277           191      0.3265         0.1152         0.9259         0.0353                0.9996                      0.6314          0.2652
  PfMSRP5 + PfRAMA + PfSERA9 + PfRH5                        277           191      0.3265         0.1152         0.9259         0.0353                0.9996                      0.6314          0.2652
  PfEBA181 + PfMSRP5 + PfRAMA + PfSERA9 + PfRH5             277           191      0.3265         0.1152         0.9259         0.0353                0.9996                      0.6314          0.2652
  PfSERA9 + PfRH5                                           276           191      0.5580         0.3146         0.9897         0.0460                0.9996                      0.9942          0.2751
  PfEBA181 + PfMSRP5 + PfSERA9 + PfRH5                      277           191      0.3973         0.1551         1.0176         0.0544                0.9996                      0.6009          0.2643
  PfMSRP5 + PfSERA9 + PfRH5                                 276           191      0.4694         0.1974         1.1164         0.0871                0.9996                      0.6514          0.2498
  PfMSRP5 + PfRAMA + PfSERA9                                277           191      0.6097         0.3164         1.1749         0.1393                0.9996                      0.4759          0.2533
  PfEBA181 + PfRAMA                                         277           191      0.6867         0.4154         1.1351         0.1427                0.9996                      0.3132          0.2147
  PfRAMA                                                    277           191      0.7079         0.4426         1.1322         0.1494                0.9996                      0.3232          0.2293
  PfMSRP5                                                   277           191      0.7740         0.5293         1.1320         0.1866                0.9996                      0.8994          0.3040
  PfEBA181 + PfMSRP51                                       277           191      0.7786         0.5086         1.1920         0.2494                0.9996                      0.7291          0.2966
  PfEBA181 + PfMSRP5 + PfRAMA + PfSERA9                     277           191      0.6844         0.3534         1.3254         0.2608                0.9996                      0.5326          0.2656
  PfSERA9                                                   277           191      1.1622         0.8602         1.5702         0.3275                0.9996                      0.0328          0.0630
  PfCyRPA + PfSERA9                                         277           191      0.6607         0.2095         2.0840         0.4795                0.9996                      0.2012          0.1962
  PfEBA181 + PfSERA9                                        277           191      1.1157         0.8100         1.5369         0.5027                0.9996                      0.0599          0.0929
  PfCyRPA                                                   277           191      0.7925         0.3481         1.8047         0.5797                0.9996                      0.4000          0.2617
  PfCyRPA + PfMSRP5 + PfSERA9                               277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfMSRP5 + PfRH5                                 277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfRAMA + PfSERA9                                277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfRAMA + PfRH5                                  277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfEBA181 + PfMSRP5 + PfSERA9                    277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfEBA181 + PfMSRP5 + PfRH5                      277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfEBA181 + PfRAMA + PfSERA9                     277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfEBA181 + PfRAMA + PfRH5                       277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfMSRP5 + PfRAMA + PfSERA9                      277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfMSRP5 + PfRAMA + PfRH5                        277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfMSRP5 + PfSERA9 + PfRH5                       277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfRAMA + PfSERA9 + PfRH5                        277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfEBA181 + PfMSRP5 + PfRAMA + PfSERA9           277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfEBA181 + PfMSRP5 + PfRAMA + PfRH5             277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfEBA181 + PfMSRP5 + PfSERA9 + PfRH5            277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfEBA181 + PfRAMA + PfSERA9 + PfRH5             277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfMSRP5 + PfRAMA + PfSERA9 + PfRH5              277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfEBA181 + PfMSRP5 + PfRAMA + PfSERA9 + PfRH5   277           191      0.5872         0.0806         4.2792         0.5993                0.9996                      0.3609          0.2443
  PfCyRPA + PfMSRP5                                         277           191      0.7493         0.1832         3.0655         0.6881                0.9996                      0.1311          0.1491
  PfCyRPA + PfRAMA                                          277           191      0.7493         0.1832         3.0655         0.6881                0.9996                      0.1311          0.1491
  PfCyRPA + PfEBA181 + PfMSRP5                              277           191      0.7493         0.1832         3.0655         0.6881                0.9996                      0.1311          0.1491
  PfCyRPA + PfEBA181 + PfRAMA                               277           191      0.7493         0.1832         3.0655         0.6881                0.9996                      0.1311          0.1491
  PfCyRPA + PfMSRP5 + PfRAMA                                277           191      0.7493         0.1832         3.0655         0.6881                0.9996                      0.1311          0.1491
  PfCyRPA + PfEBA181 + PfMSRP5 + PfRAMA                     277           191      0.7493         0.1832         3.0655         0.6881                0.9996                      0.1311          0.1491
  PfRAMA + PfSERA9                                          277           191      0.9129         0.5488         1.5185         0.7256                0.9996                      0.7739          0.3102
  PfCyRPA + PfRH5                                           277           191      0.8149         0.1980         3.3536         0.7768                0.9996                      0.1562          0.1642
  PfCyRPA + PfEBA181 + PfSERA9                              277           191      0.8149         0.1980         3.3536         0.7768                0.9996                      0.1562          0.1642
  PfCyRPA + PfEBA181 + PfRH5                                277           191      0.8149         0.1980         3.3536         0.7768                0.9996                      0.1562          0.1642
  PfCyRPA + PfSERA9 + PfRH5                                 277           191      0.8149         0.1980         3.3536         0.7768                0.9996                      0.1562          0.1642
  PfCyRPA + PfEBA181 + PfSERA9 + PfRH5                      277           191      0.8149         0.1980         3.3536         0.7768                0.9996                      0.1562          0.1642
  PfCyRPA + PfEBA181                                        277           191      0.8770         0.2758         2.7890         0.8240                0.9996                      0.0594          0.0941
  PfMSRP5 + PfSERA9                                         277           191      1.0498         0.6789         1.6231         0.8271                0.9996                      0.7816          0.3178
  PfEBA181 + PfMSRP5 + PfSERA9                              277           191      1.0508         0.6597         1.6738         0.8348                0.9996                      0.7149          0.3110
  PfEBA181                                                  277           191      1.0325         0.7435         1.4340         0.8485                0.9996                      0.0032          0.0125
  PfEBA181 + PfRAMA + PfSERA9                               277           191      0.9999         0.6005         1.6647         0.9996                0.9996                      0.6747          0.3042

Details of the analyses are described in [*SI Methods*](#si1){ref-type="sec"}. BH, Benjamini--Hochberg; CI, confidence interval; ZPH, assumption testing using the cox.zph function from the *survival* package in R.

###### 

Comparison of in vivo PMRs in individuals with positive or negative IgG responses to *P. falciparum* antigens alone or in combination

  Univariate, Wilcoxon test                       Logistic regression                                                                                          
  ----------------------------------------------- --------------------- -------------------- ----- --------------------- -------- -------- ---------- -------- --------
  PfMSRP5 + PfRh5                                 197                   2.92 (0.851--4.32)   18    1.5 (0.501--2.96)     0.0288   0.3094   −0.8117    0.1609   0.9584
  PfRAMA                                          183                   2.92 (0.853--4.31)   33    2.11 (0.589--3.01)    0.0373   0.3094   −0.4961    0.2905   0.9584
  PfMSRP5 + PfSERA9 + PfRh5                       205                   2.86 (0.851--4.29)   10    0.696 (0.474--2.96)   0.065    0.3094   −0.6954    0.3485   0.9584
  PfMSRP5 + PfRAMA                                193                   2.91 (0.85--4.31)    23    2.11 (0.595--2.97)    0.0719   0.3094   −0.3957    0.4719   0.9584
  PfSERA9 + PfRh5                                 193                   2.91 (0.851--4.31)   22    1.05 (0.619--3.09)    0.0725   0.3094   −0.4766    0.3348   0.9584
  PfRh5                                           172                   2.93 (0.86--4.35)    40    2.17 (0.646--3.64)    0.0753   0.3094   −0.3243    0.3891   0.9584
  PfSERA9                                         115                   3 (0.779--4.43)      101   2.55 (0.785--3.74)    0.0867   0.3094   −0.4128    0.1655   0.9584
  PfRAMA + PfRh5                                  205                   2.86 (0.851--4.29)   10    0.696 (0.501--2.96)   0.0912   0.3094   −0.4959    0.5166   0.9584
  PfMSRP5 + PfRAMA + PfRh5                        206                   2.85 (0.851--4.28)   10    0.696 (0.501--2.96)   0.0927   0.3094   −0.5112    0.5035   0.9584
  PfEBA181 + PfRAMA                               188                   2.88 (0.851--4.3)    28    2.1 (0.572--3.26)     0.0967   0.3094   −0.2669    0.5874   0.9584
  PfEBA181 + PfMSRP5 + PfRh5                      203                   2.86 (0.84--4.3)     13    2.21 (0.52--3.01)     0.112    0.3258   −0.6747    0.3038   0.9584
  PfMSRP5                                         157                   2.96 (0.85--4.38)    59    2.45 (0.776--3.53)    0.14     0.3349   −0.183     0.5975   0.9584
  PfEBA181 + PfMSRP5 + PfRAMA                     196                   2.85 (0.845--4.3)    20    2.19 (0.632--3.12)    0.147    0.3349   −0.04626   0.9361   0.9584
  PfCyRPA                                         210                   2.78 (0.758--4.15)   6     4.23 (3.12--4.46)     0.151    0.3349   0.9362     0.33     0.9584
  PfEBA181 + PfMSRP5 + PfSERA9 + PfRh5            207                   2.84 (0.84--4.27)    9     0.723 (0.52--3.01)    0.157    0.3349   −0.4743    0.5347   0.9584
  PfEBA181 + PfMSRP5 + PfRAMA + PfRh5             207                   2.84 (0.84--4.27)    9     0.723 (0.52--3.01)    0.184    0.3464   −0.4265    0.5858   0.9584
  PfEBA181 + PfRAMA + PfRh5                       207                   2.84 (0.84--4.27)    9     0.723 (0.52--3.01)    0.184    0.3464   −0.4265    0.5858   0.9584
  PfEBA181                                        101                   3.04 (0.673--4.59)   115   2.67 (0.84--3.7)      0.196    0.3484   −0.3456    0.2823   0.9584
  PfEBA181 + PfRh5                                192                   2.85 (0.82--4.32)    24    2.23 (0.678--3.25)    0.227    0.3648   −0.2932    0.5275   0.9584
  PfMSRP5 + PfSERA9                               181                   2.86 (0.85--4.29)    35    2.65 (0.595--4.04)    0.228    0.3648   −0.08107   0.8441   0.9584
  PfEBA181 + PfSERA9 + PfRh5                      199                   2.84 (0.81--4.3)     17    2.12 (0.681--3.12)    0.286    0.3815   −0.2381    0.6616   0.9584
  PfEBA181 + PfRAMA + PfSERA9                     192                   2.85 (0.82--4.26)    24    2.3 (0.632--3.6)      0.29     0.3815   −0.07025   0.8893   0.9584
  PfRAMA + PfSERA9                                192                   2.85 (0.82--4.26)    24    2.3 (0.632--3.6)      0.29     0.3815   −0.07025   0.8893   0.9584
  PfEBA181 + PfMSRP51                             173                   2.91 (0.756--4.34)   43    2.75 (0.789--3.39)    0.303    0.3815   −0.02043   0.9584   0.9584
  PfEBA181 + PfMSRP5 + PfRAMA + PfSERA9           199                   2.84 (0.81--4.27)    17    2.45 (0.669--3.44)    0.31     0.3815   0.05237    0.9301   0.9584
  PfMSRP5 + PfRAMA + PfSERA9                      199                   2.84 (0.81--4.27)    17    2.45 (0.669--3.44)    0.31     0.3815   0.05237    0.9301   0.9584
  PfEBA181 + PfMSRP5 + PfRAMA + PfSERA9 + PfRh5   208                   2.83 (0.82--4.26)    8     1.76 (0.632--3.27)    0.37     0.3947   −0.227     0.7758   0.9584
  PfEBA181 + PfRAMA + PfSERA9 + PfRh5             208                   2.83 (0.82--4.26)    8     1.76 (0.632--3.27)    0.37     0.3947   −0.227     0.7758   0.9584
  PfMSRP5 + PfRAMA + PfSERA9 + PfRh5              208                   2.83 (0.82--4.26)    8     1.76 (0.632--3.27)    0.37     0.3947   −0.227     0.7758   0.9584
  PfRAMA + PfSERA9 + PfRh5                        208                   2.83 (0.82--4.26)    8     1.76 (0.632--3.27)    0.37     0.3947   −0.227     0.7758   0.9584
  PfEBA181 + PfMSRP5 +Pf SERA9                    186                   2.85 (0.801--4.28)   30    2.73 (0.738--3.86)    0.391    0.4036   −0.03299   0.9408   0.9584
  PfEBA181 + PfSERA9                              138                   2.89 (0.692--4.31)   78    2.73 (0.866--3.98)    0.713    0.713    −0.1537    0.6317   0.9584

Details of the analyses are described in [*SI Methods*](#si1){ref-type="sec"}. BH, Benjamini--Hochberg; IQR, interquartile range; PMR, parasite multiplication rate. Bold rows indicate statistical significance in the univariate analysis (unadjusted *P* value \< 0.05).

Combining Targets at Multiple Steps of Invasion Can Increase Synergy. {#s4}
---------------------------------------------------------------------

These data suggest that IgG responses to these antigens contribute to naturally acquired immunity to malaria and also suggest that combining these antigens in a vaccine could improve protective efficacy. We therefore assessed whether combining purified total IgG from different targets could act synergistically to inhibit parasite growth in vitro. The amount of anti-PfRAMA IgG was limiting, so we were only able to test this antibody in combination with anti-PfRh5 and anti-PfCyRPA IgG. Antibody interactions were evaluated over a range of concentrations by a fixed-ratio method ([@r29]), and IC~50~ values were used to calculate the 50% fractional inhibitory concentration (FIC~50~). FIC~50~ values at different concentration ratios were used to construct isobolograms for each antibody combination ([Fig. 3](#fig03){ref-type="fig"}). Several combinations of antibodies showed deviations from the diagonal line that would indicate a purely additive interaction under Loewe additivity. Combinations of anti-PfCyRPA/PfSERA9, anti-PfCyRPA/PfRAMA, anti-PfRh5/PfRAMA, and anti-PfRh5/PfMSRP5 all showed deviations below the diagonal, indicating a trend toward synergy ([Fig. 3 *C* and *F*--*H*](#fig03){ref-type="fig"}), whereas the combinations of anti-PfEBA181/PfCyRPA and anti-PfEBA181/PfSERA9 showed curves above the diagonal, indicating a trend toward antagonism ([Fig. 3 *A* and *E*](#fig03){ref-type="fig"}). Several combinations of antibodies with anti-PfRh5 had different effects at high and low concentrations of anti-PfRh5 (FIC~50~ \> 1) ([Fig. 3 *D*, *I*, and *J*](#fig03){ref-type="fig"}), emphasizing that the ratio in which two antibodies are combined can determine whether a given combination has a greater effect than that achieved by each antibody alone. To test the statistical significance of these interactions, we calculated an interaction index for each combination and modeled its associated 95% CI using Monte Carlo simulation of the measurement errors in the IC~50~ values ([Fig. S5](#sfig05){ref-type="fig"}). This analysis showed no combination had CIs that did not include one at all concentrations tested, meaning that none were unfailingly either synergistic or antagonistic. However, the combinations of anti-PfRh5/PfRAMA and anti-PfCyRPA/PfRAMA were those with the most consistently synergistic interactions, while as noted above, several combinations including anti-PfRh5 combinations were significantly synergistic at low concentrations of anti-PfRh5 but not high concentrations ([Fig. S5](#sfig05){ref-type="fig"}). Combinations that included PfMSRP5 had particularly wide CIs, decreasing the statistical weight that can be put to them.

![Combinatorial screening reveals antibody pairs with synergistic effects. Isobolograms showing the combined effect of fixed-ratio mixtures (5:0, 4:1, 3:2, 2:3, 1:4, and 0:5) of purified polyclonal antibodies on erythrocyte invasion by *P. falciparum* 3D7. In each case *x* and *y* axes represent the FIC~50~ values associated with the two antibodies in each combination: EBA181/CyRPA (*A*), MSPR5/CyRPA (*B*), SERA9/CyRPA (*C*), Rh5/CyRPA (*D*), SERA9/EBA181 (*E*), CyRPA/RAMA (*F*), Rh5/RAMA (*G*), Rh5/MSRP5 (*H*), SERA9/Rh5 (*I*), and EBA181/Rh5 (*J*). Dashed lines represent the expected result under Loewe additivity (sum of FIC~50~s equal to 1). Points below this line are suggestive of synergistic inhibition, while points above it suggest antagonistic inhibition ([@r38]).](pnas.1702944114fig03){#fig03}

![CIs for synergy/antagonism in antibody combinations. Dose--response data were analyzed to calculate an interaction index, calculated as the sum of the two FIC~50~ values for each ratio. CIs were computed for the interaction indices by propagating the errors in the logIC~50~ values by Monte Carlo simulation. Antibody combinations are shown on the *y* axis with a ratio given for the proportions in which the first and second antibodies are mixed, while the interaction index is shown on the *x* axis. Interaction indices \>1 represent antagonism, while those \<1 represent synergy.](pnas.1702944114sfig05){#sfig05}

One potential explanation for the combinatorial effects observed is that simultaneously blocking targets that act at different steps during invasion may not have the same effect as blocking targets that act at the same step of invasion. While the specific function of PfRh5 during invasion has been studied in detail ([@r30]), the role of the other antigens is much less well-defined. We therefore carried out video microscopy studies, incubating purified late schizonts from the 3D7 *P. falciparum* strain with purified IgG at the maximal concentration for each target. Schizont egress and subsequent merozoite--erythrocyte interactions were recorded using a recently described imaging platform ([@r31]), and multiple invasion associated parameters were quantified from these videos. All antibodies decreased the number of merozoite--erythrocyte contacts made after each egress, but anti-PfMSRP5 had the most significant effect at this very early stage of invasion ([Fig. 4*A*](#fig04){ref-type="fig"} and [Movies S1](#d35e3367){ref-type="supplementary-material"} and [S2](#d35e3371){ref-type="supplementary-material"}), consistent with its presence on the merozoite surface. Anti-PfEBA181 was the only IgG that had a marked effect on prolonging the duration of merozoite--erythrocyte interactions ([Fig. 4*B*](#fig04){ref-type="fig"} and [Movie S3](#d35e3379){ref-type="supplementary-material"}), suggesting that it acts after the initial contact has occurred but before active invasion has begun, as has been suggested for other members of the same family of invasion ligands ([@r30]). By contrast, anti-PfRh5, PfCyRPA, and PfSERA9 had no effect on the duration of contacts but did have a significant effect on the severity of erythrocyte deformations ([Fig. 4*C*](#fig04){ref-type="fig"} and [Movies S4--S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1702944114/-/DCSupplemental)), with the majority of merozoites inducing little to no deformation ([Fig. 4*D*](#fig04){ref-type="fig"}). Action at this late stage of invasion, interpreted as representing tight junction formation, has been previously reported for PfRh5 ([@r30]). Finally, anti-PfRAMA IgG had no effect on the number or severity of deformation events ([Fig. 4 *D* and *E*](#fig04){ref-type="fig"} and [Movie S7](#d35e3413){ref-type="supplementary-material"}), indicating that it inhibits invasion much later in the process after the tight junction has been established. Taking the data together, these targets seem to function at discrete temporal steps during invasion, as summarized in [Fig. 4](#fig04){ref-type="fig"}: (*i*) PfMSRP5, (*ii*) PfEBA181, (*iii*) PfRh5/PfCyRPA/PfSERA9, and (*iv*) PfRAMA. It is notable that combinations of antibodies that target both steps 3 and 4 (PfRh5/PfRAMA and PfCyRPA/PfRAMA) were the most consistently synergistic in GIA assays. Similarly, the combinations of antigen-specific IgG responses that were associated with protection from febrile malaria in immunoepidemiological studies ([Fig. 2](#fig02){ref-type="fig"}) all targeted antigens operating at multiple distinct steps of invasion, rather than multiple antigens operating at the same step. Focusing combinatorial strategies on nonoverlapping steps during invasion may therefore maximize the chance of synergistic effects.

![Video microscopy of erythrocyte invasion reveals discrete roles for candidate antigens. More than 40 egress events were recorded in the presence of IgG against each target, and a range of invasion-related phenotypes was quantitated. (*A*) Number of merozoite contacts that occur after each egress event. (*B*) Time taken (s) between merozoite contact and erythrocyte deformation, sometimes referred to as preinvasion, quantitated for merozoites that went on to productively invade erythrocytes (invaders) and those that did not (noninvaders). Total number of events analyzed in *A* and *B*: control, 63; anti-PfMSRP5, 65; anti-PfEBA181, 49; anti-PfSERA9, 53; anti-PfRh5, 50; anti-PfRAMA, 55; anti-PfCyRPA, 52. (*C*) Examples of deformation scores from 0 (no deformation) to 3 \[strong deformation ([@r26])\]. (*D*) Range of deformation scores for every merozoite--erythrocyte interaction, quantitated for both invaders and noninvaders. (*E*) Number of deformation events that take place after each egress event. \**P* \< 0.06, \*\**P* \< 0.001, \*\*\**P* \< 0.0005. (*F*) Schematic summarizing the data in this study for each antigen: the phase of invasion they function in, as determined by video microscopy (numbered black boxes one to four); the synergistic (dark blue arrows), antagonistic (black bars), and mixed synergistic/antagonistic interactions (purple diamonds) between antibodies targeting these antigens based on isobologram analyses; the immunoprotective combinations of antigens revealed in the Malian cohort study (connected circles); and the physical location of the proteins on merezoites (beige boxes).](pnas.1702944114fig04){#fig04}

Discussion {#s5}
==========

Malaria vaccine candidate identification has so far largely consisted of detailed preclinical studies targeting a single antigen at a time, with two significant detrimental consequences. Firstly, few antigens can be studied, leaving the majority of potential targets in the *P. falciparum* genome unexplored. Secondly, such single targets are particularly susceptible to failure due to allele-specific responses, as if variants in that antigen evolve that are not recognized by the dominant vaccine-induced response and there is nothing to prevent vaccine escape. Next-generation malaria vaccines will need to target multiple antigens, preferably in combinations that induce synergistic responses. Such a design would mimic what is now becoming clear about natural immunity to malaria, where the breadth of response to multiple antigens is a much stronger predictor of protection than the response to any single antigen ([@r13]). This study performed a systematic screen of 29 *P. falciparum* antigens alone and together and complemented in vitro inhibition and mechanistic studies with an investigation of immune responses in the field to prioritize candidates and combinations. Multiple targets were identified that induced antibodies that inhibited *P. falciparum* growth, and several combinations of these antibodies were synergistic in vitro, mirroring immunoepidemiological data that combinations of antibodies against the same targets were associated with protection in vivo at a field site in Mali. This study also highlights the complexity of antibody interactions. For example, in in vitro invasion studies, anti-PfRh5 and anti-PfEBA181 IgG interact antagonistically at high levels of anti-Rh5 IgG but synergistically at low levels of anti-Rh5 IgG. Intriguingly, the latter scenario is consistent with seroepidemiological data that have shown that anti-RH5 IgG associates with malaria protection despite having relatively low reactivity ([@r28]).

Although screening 29 antigens in this manner is a significant step forward, it represents perhaps only one-third of the antigens that are exposed on the parasite surface during erythrocyte invasion. The number of antigens that could be screened was in part limited by the HEK293E expression system. This system has several advantages, most significantly that by being eukaryotic it is more likely to produce antigens that are functional and will therefore best mimic their native counterparts. However, significant amounts of antigen (up to 1 mg) are required for immunization studies such as these, and in general only 70--80% of antigens can be expressed at these levels in the HEK293E system ([@r10], [@r32]). The HEK293E expression system may also not suit all antigens, so there is a risk of false negatives, as there is in any systematic screen. This may explain the absence of inhibitory antibodies generated against MSP2, for example, which has previously been extensively investigated as a blood-stage vaccine candidate ([@r33]). Alternative eukaryotic expression systems such as the insect cell system used recently for successful expression of PfRh5 ([@r34]), or the wheat germ cell-free system used for its binding partner PfRIPR ([@r35]), may be required in addition to perform truly comprehensive blood-stage antigen screens. Testing for effective strain transcendence is also a critical consideration. Now that the true extent of global genomic variation has been revealed by large-scale genome sequencing studies ([@r6]), it is apparent that there are several geographic regions that have distinct genomic repertoires but for which there are no commonly available in vitro adapted isolates for testing. Identification, expansion, and distribution of *P. falciparum* isolates from these areas, specifically East Africa, India/Bangladesh, and Papua New Guinea, will be an essential step to enable more comprehensive assessment of strain transcendence. In addition, efforts to standardize growth inhibition assays need to focus on miniaturization, to allow testing of a larger number of isolates when antibody volume is limiting, as it was here.

Despite these limitations, several antigens and combinations were identified in this study. As well as identifying targets, this work also suggests a logical rationale to guide the selection of potentially synergistic combinations---targeting multiple independent steps in the same pathway, in this case erythrocyte invasion. The mechanism by which a given combination results in synergy is not known, but it has been previously suggested that kinetics could play a role, where binding to some merozoite surface antigens might slow invasion down sufficiently to allow other antibodies to bind ([@r36]). This model certainly fits with some mechanisms uncovered by video microscopy, such as anti-EBA181, which appears to increase the duration of merozoite--erythrocyte contacts and shows some evidence for synergy with anti-Rh5. However, further work is clearly required to truly understand the mechanisms of inhibition, and the strategy of targeting multiple steps is not the only viable approach, as recent studies of the AMA1--RON2 interaction that forms a complex late during erythrocyte invasion show that in this case inhibiting both members of the same complex is more effective than targeting either alone ([@r37]).

Targeting multiple antigens will require parasites to simultaneously evolve variants in multiple antigens to avoid vaccine-induced immune responses, which should slow the emergence of resistance at the population level. Targeting antigens that operate at distinct steps in the same pathway offers an additional level of redundancy at the single parasite level by requiring individual merozoites to avoid inhibition of multiple temporally distinct steps. This same theoretical approach may be applied to other malaria vaccine targets, such as the recognition and invasion of hepatocytes by *Plasmodium* sporozoites for pre-erythrocytic stage vaccines or gamete development within the *Anopheles* midgut for transmission-blocking vaccines. A deeper understanding of all of these biological processes coupled with more systematic reverse vaccinology approaches will help further drive the development of the next generation of more complex, and more effective, malaria vaccine combinations.

Methods {#s6}
=======

Recombinant Merozoite Protein Production. {#s7}
-----------------------------------------

Recombinant extracellular domains of merozoite proteins were produced by transient transfection of HEK293 cells, as previously described ([@r11]). Culture supernatants were collected after 6 d and tested for expression of recombinant proteins by ELISA, using a mouse monoclonal antibody that binds the CD4 tag (OX68) to detect expressed protein.

Protein Purification and Quality Assessment. {#s8}
--------------------------------------------

Recombinant merozoite proteins were purified from pooled transfection supernatants using HisTrap HP columns (GE Healthcare). Proteins were eluted using an elution buffer containing 400 mM imidazole and then dialyzed against PBS ([d]{.smallcaps}-tube Dialyzer; Novagen). The concentration of protein samples was determined by absorbance at 280 nm, using in silico predicted extinction coefficients (DS Gene version 1.5; Accelrys), and quality assessed by ELISA and reducing SDS/PAGE.

Antibody Purification and Quality Assessment. {#s9}
---------------------------------------------

Rabbit polyclonal antibodies were raised against purified recombinant proteins by Cambridge Research Biochemicals after ethical assessment. Sera was tested for activity against the appropriate antigen by ELISA and then purified using a HiTrap Protein G HP column (GE Healthcare). Purified antibodies were dialyzed against PBS (or RPMI 1640 for invasion assays), tested for activity against the appropriate antigen by ELISA, and quality assessed by reducing SDS/PAGE.

Parasite Culture and GIA Assays. {#s10}
--------------------------------

*P. falciparum* 3D7 and Dd2 parasites were cultured in human O+ erythrocytes. GIAs were carried out in round-bottom 96-well plates, with a culture volume of 100 µL per well at a hematocrit of 2%. Synchronized parasites were incubated with antibodies for 24 h at 37 °C before being stained with 1:5,000 SYBR Green I (Invitrogen) to detect parasite DNA ([@r12]). Invasion efficiency was calculated by comparing invasion in the presence of a given antibody concentration to invasion in the absence of antibodies. All experiments were carried out in triplicate. Use of erythrocytes from human donors for *P. falciparum* culture was approved by the NHS Cambridgeshire 4 Research Ethics Committee, and all donors supplied written informed consent.

Human Cohort Study. {#s11}
-------------------

The details of the Malian prospective cohort study have been described ([@r28]). The Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at the University of Sciences, Technique and Technology of Bamako, and the Institutional Review Board of the National Institute of Allergy and Infectious Diseases, National Institutes of Health approved the Malian cohort study, which is registered on <https://clinicaltrials.gov/> (no. NCT01322581). Written, informed consent was obtained from adult participants and from the parents or guardians of participating children. For this study, malaria episodes were defined as an asexual parasite density by peripheral blood smear of \>2,500 parasites per µL, an axillary temperature of ≥37.5 °C within 24 h, and no other cause of fever discernible by physical examination.

Immunoepidemiology. {#s12}
-------------------

Plasma IgG levels against target antigens were determined by ELISA as previously described ([@r26]) and outlined in detail in [SI Methods](#si1){ref-type="sec"}. In brief, plasma samples from each individual were tested in duplicate, alongside the same positive controls (hyperimmune plasma) and negative controls (unexposed donor plasma). ODs, adjusted for background, were converted to arbitrary units (AUs) by dividing the test OD by the mean OD for negative controls plus 3 SDs, and AU \> 1 was defined as a positive IgG response. A base Cox proportional hazards model was used to determine whether positive IgG responses to any of the 63 possible reactivity combinations was associated with a reduction in risk of clinical malaria, using time from first *P. falciparum* blood-stage inoculum (estimated as the midpoint between the last *Plasmodium*-PCR--negative visit and the first *Plasmodium*-PCR--positive visit) to first febrile malaria episode as the dependent variable and controlling for potential confounding variables ([Table S3](#st03){ref-type="table"}). In vivo PMRs were estimated using qPCR-determined parasite density at the first PCR-positive visit and the number of days between the first *P. falciparum* blood-stage inoculum and the first smear-positive visit. Analyses were performed in R version 3.3.0 ([www.R-project.org](http://www.r-project.org/)) or Prism version 5.0d (GraphPad Software).

Isobologram Analyses. {#s13}
---------------------

Dose--response assays were first carried out to obtain the IC~50~ of the individual antibodies. Interactions were then assessed over a range of concentrations by a fixed-ratio method based on the IC~50~ values ([@r29]). FIC~50~s were calculated on the basis of the IC~50~s obtained per assay for each antibody (the FIC~50~ is equal to the IC~50~ of antibody A in combination with antibody B/IC~50~ of antibody A alone) and used to plot isobolograms. An interaction index was calculated by summing the FIC~50~ derived from each of the two antibodies in any combination and CIs calculated using Monte Carlo simulation based on the error terms in the fitted IC~50~ curves.

Video Microscopy. {#s14}
-----------------

Highly synchronous *P. falciparum* 3D7 late-stage schizonts were purified using a magnetic column (Miltenyi Biotec) and placed in a Secure-Seal hybridization chamber (Sigma-Aldrich) mounted on a glass slide. All live-cell experiments were performed in a homebuilt environmental chamber at 37 °C with a humidified gas supply. Imaging was performed using a Nikon Eclipse TI-E inverted microscope through a Plan Apo λ 40× 0.95 N.A. dry objective (Nikon). Time-lapse videos were recorded on a Grasshopper3 GS3-U3-23S6M-C camera (Point Gray Research) at four frames per second. A custom MATLAB program was employed to perform image recording and statistical analysis.

SI Methods {#si1}
==========

Recombinant Merozoite Protein Production. {#si2}
-----------------------------------------

Recombinant extracellular domains of merozoite proteins fused with rat CD4 domains 3 and 4 and hexahistidine tags were produced by transient transfection of mammalian cell culture using PEI, as previously described ([@r11]). Briefly, HEK293E or HEK293F cells, cultured in suspension in Freestyle 293 media (Gibco) supplemented with (HEK293E cells only) 1% FCS (Sigma), penicillin (100 units/mL; Sigma), streptomycin (0.1 mg/mL; Sigma), and geneticin (50 µg/mL; Sigma), were transfected with an expression plasmid encoding the protein of interest using linear 25 kDa PEI (Polyscience) mixed in a ratio of 2:1 (PEI:DNA, wt/wt) in 2 mL of unsupplemented media. Transfected cell culture supernatants were collected after 6 d and tested for expression of recombinant proteins by ELISA, using nickel-coated microtiter plates (Qiagen) to immobilize hexahistidine-tagged proteins and a mouse monoclonal antibody that binds the CD4 tag (OX68) to detect expressed protein. In silico predictions of molecular weight, isoelectric point, aliphatic index, and grand average of hydropathicity index were calculated using DS Gene (version 1.5; Accelrys).

Protein Purification and Quality Assessment. {#si3}
--------------------------------------------

Recombinant merozoite proteins were purified from pooled transfection supernatants by IMAC using HisTrap HP columns (GE Healthcare). Proteins were eluted from the column using an elution buffer containing 400 mM imidazole and then dialyzed against PBS ([d]{.smallcaps}-tube Dialyzer; Novagen). The concentration of protein samples was determined by absorbance at 280 nm, using in silico-predicted extinction coefficients (DS Gene version 1.5; Accelrys). Quality and quantity of each purified sample were assessed by ELISA and reducing SDS/PAGE, using premade NuPAGE 4--12% Bis--Tris buffered polyacrylamide gels (Novex) and Mops running buffer. Proteins were visualized using SYPRO Orange dye (Sigma) and a Typhoon (GE Healthcare) laser scanner. Images were adjusted for brightness and contrast in Abode Photoshop CS2.

Antibody Purification and Quality Assessment. {#si4}
---------------------------------------------

Bespoke rabbit polyclonal antibodies raised against the purified recombinant proteins were prepared by Cambridge Research Biochemicals after ethical assessment. Rabbits were immunized four times with a total amount of 0.3--0.6 mg of each purified antigen and exsanguinated after 77 d. Each harvested antibody sera was tested for activity against the appropriate antigen by ELISA and then purified using a HiTrap Protein G HP column (GE Healthcare). Total IgG antibodies were eluted from the column using 0.1 M glycine--HCl (pH 2.7) and immediately neutralized with 2 M Tris⋅HCl (pH 9.5). Purified antibodies were dialyzed against PBS and the concentration of IgG determined by absorbance at 280 nm. Each purified polyclonal IgG sample was tested for activity against the appropriate antigen by ELISA, with 500 ng target protein immobilized in each well. The quality of purification was assessed by reducing SDS/PAGE. Polyclonal antibody samples were dialyzed against RPMI 1640, without phenol red (Gibco), before use in invasion assays.

Parasite Culture and GIA Assays. {#si5}
--------------------------------

The 3D7 and Dd2 parasites were obtained from MR4 (<https://www.beiresources.org/>). *P. falciparum* parasite strains were cultured in human O+ erythrocytes at 5% hematocrit in complete medium (RPMI-1640 supplemented with Albumax), under an atmosphere of 1% O~2~, 3% CO~2~, and 96% N~2~. Use of erythrocytes from human donors for *P. falciparum* culture was approved by the NHS Cambridgeshire 4 Research Ethics Committee, and all donors supplied written informed consent. GIA assays were carried out in round-bottom 96-well plates, with a culture volume of 100 µL per well at a hematocrit of 2%. Parasites were synchronized at early stages with 5% (wt/vol) [d]{.smallcaps}-sorbitol (Sigma), and trophozoite stage parasites were incubated in the presence or absence of antibodies for 24 h at 37 °C inside a static incubator culture chamber (VWR), gassed with 1% O~2~, 3% CO~2~, and 96% N~2~. All antibodies were dialyzed into RPMI before addition into GIA assays. At the end of the incubation period, cultures were harvested and fixed, and parasitized erythrocytes were stained with 1:5,000 SYBR Green I (Invitrogen), as described previously ([@r12]). SYBR Green I stained samples were excited with a 488 nm UV laser on a BD Calibur flow cytometer (BD Biosciences) and detected with a 530/30 filter. BD FACS Diva software (BD Biosciences) was used to analyze 50,000 events for each sample. FSC and SSC voltages of 423 and 198, respectively, and a threshold of 2,000 on FSC were applied to gate the erythrocyte population. The data collected were further analyzed with FlowJo (Tree Star). Invasion efficiency was calculated by comparing invasion in the presence of a given antibody concentration to invasion in the absence of antibodies. All experiments were carried out in triplicate. GraphPad Prism (GraphPad Software) was used to plot the parasitemia data.

Cross-Reactivity. {#si6}
-----------------

To assess the specificity of the polyclonal, purified anti-EBA181, anti-MSRP5, and anti-SERA9 antibodies were tested for activity against the recombinant extracellular domains of other EBA, MSP7-like, and SERA family members, respectively, by ELISA. Four members of the SERA family were not included in the assay because we were unable to produce them by transient transfection. The purified antibodies were diluted and mixed with or without purified, recombinant CD4 tag-only protein at a ratio of 1:10 antibody:tag protein (wt/wt; final antibody concentration, 100 µg/mL) to eliminate activity against the tag domains common to all ectodomains. The antibodies were incubated at room temperature for 30 min before use. The undepleted and depleted antibodies were tested for activity against recombinant, biotinylated extracellular domains of EBA, MSP7-like, and SERA family proteins, immobilized on the surface of streptavidin-coated microtiter plates, by ELISA. A high antibody concentration (100 µg/mL) was used in the assay to detect any low titer cross-reactivity.

Human Cohort Study. {#si7}
-------------------

The details of the Malian prospective cohort study have been described ([@r27], [@r28]). The Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at the University of Sciences, Technique and Technology of Bamako, and the Institutional Review Board of the National Institute of Allergy and Infectious Diseases, National Institutes of Health approved the Malian cohort study, which is registered on <https://clinicaltrials.gov/> (no. NCT01322581). Written, informed consent was obtained from adult participants and from the parents or guardians of participating children. For this study, malaria episodes were defined as an asexual parasite density by peripheral blood smear of \>2,500 parasites per µL, an axillary temperature of ≥37.5 °C within 24 h, and no other cause of fever discernible by physical examination.

Determination of the First-Detectable Blood-Stage Infection. {#si8}
------------------------------------------------------------

Blood was collected by finger stick for dried blood spots and thick blood smears during scheduled clinic visits occurring at 2-wk intervals over 7 mo or during unscheduled acute visits. Smears were stained with Giemsa and read contemporaneously if the participant demonstrated signs or symptoms of illness. Individuals with positive smears at any level of *Plasmodium* parasitemia were treated according to the National Malaria Control Program guidelines in Mali. At the completion of the first year of the study, dried blood spots and the remainder of the smears were retrospectively assessed for the presence of parasitemia in chronological order until the first *P. falciparum*-positive sample by PCR. Parasite densities were estimated by qPCR from DNA extracted from dried blood spots as previously described ([@r1]).

Immunoepidemiology. {#si9}
-------------------

Plasma IgG levels against PfCyRPA, PfEBA181, PfMSRP5, PfRAMA, PfSERA9, and rat Cd4 domains 3 + 4 were determined by ELISA as previously described ([@r28]) except that PBS was substituted for HBS. Plasma samples from each individual were always tested in duplicate against all five antigens concurrently in consecutive wells of the same plate. The same positive controls (hyperimmune plasma) known to react to *P. falciparum* antigens and negative controls (unexposed donor plasma) were run in duplicate on each plate. Identical positive controls allowed for normalization between plates to account for plate-to-plate and day-to-day variation. Average background OD from rat-Cd4--coated wells was subtracted from the average OD for *P. falciparum* antigen-coated wells to obtain antigen-specific OD values. Plasma samples obtained from 24 US residents with no history of malaria and no travel to malaria-endemic countries were used as negative controls. ODs were converted to AUs by dividing the test OD by the mean OD for 24 malaria-naïve US donors plus 3 SDs. AU \> 1 defined a positive IgG response. IgG reactivity data for PfRH5 and PfAMA1 included in subsequent analyses have been described previously ([@r28]).

A base Cox proportional hazards model was used to determine whether positive IgG responses to any of the 63 possible reactivity combinations for PfCyRPA, PfEBA181, PfMSRP5, PfRAMA, PfSERA9, and PfRH5 associated with a reduction in risk of clinical malaria in 63 separate analyses. Specifically, the dependent variable was time from first *P. falciparum* blood-stage inoculum (estimated as the midpoint between the last *Plasmodium*-PCR--negative visit and the first *Plasmodium*-PCR--positive visit) to first febrile malaria episode. Potential confounding variables included in all base models were age as a continuous variable and sickle cell trait, anemia status, and gender as categorical variables. The Cox proportional hazard assumption was tested with the cox.zph function in the *survival* package. Hazard ratios, 95% CIs, *P* values, Benjamini--Hochberg adjusted *P* values (false discovery rates), and *P* values for assumption testing for all possible combinations are in [Table S3](#st03){ref-type="table"}. For the combinations that demonstrated statistically significant reduction in malaria risk, additional covariates were added that included IgG responses to any antigen not included in the combination of interest and IgG reactivity to PfAMA1 (as terciles ordered by low, medium, and high responders), which served as a proxy for previous malaria exposure. The in vivo PMR was approximated by dividing the qPCR-determined parasite density at the first *Plasmodium*-PCR--positive visit by the number of days between the first *P. falciparum* blood-stage inoculum (described above) and the first *Plasmodium*-PCR--positive visit. For each IgG reactivity combination, the log~10~(PMR + 1) was compared between positive and negative responders by Wilcoxon test and using a logistic regression model. For the latter, PMR (dichotomized using the median PMR) was the response variable, and IgG response (positive/negative), age (in years), sickle cell trait, anemia status, and gender were independent variables ([Table S4](#st04){ref-type="table"}). Analyses involving PMRs were limited to antigen combinations for which there were at least six positive IgG responders to minimize spurious associations. Analyses were performed in R version 3.3.0 ([www.R-project.org](http://www.r-project.org/)) or Prism version 5.0d (GraphPad Software).

Isobologram Analyses. {#si10}
---------------------

Dose--response assays were first carried out to obtain the IC~50~ of the individual antibodies. Interactions were then assessed over a range of concentrations by a fixed-ratio method based on the IC~50~ values ([@r29]). Briefly, antibody dilutions were made to allow the IC~50~ of the individual antibodies to fall at about the fourth twofold serial dilution. Stock solutions were then prepared at five times the IC~50~ of each antibody. Solutions were combined at fixed ratios of 5:0, 4:1, 3:2, 2:3, 1:4, and 0:5 for antibody A--antibody B. These starting solutions were serially diluted across six twofold dilutions. The plates were processed at the end of the incubation period (24 h), cultures were harvested and fixed, and parasitized erythrocytes were stained with 1:5,000 SYBR Green I (Invitrogen) and analyzed as described above. FIC~50~s were calculated on the basis of the IC~50~s obtained per assay for each antibody (the FIC~50~ is equal to the IC~50~ of antibody A in combination with antibody B/IC~50~ of antibody A alone). The mean sums of the FIC~50~s were calculated for all of the combinations tested and were based on the results obtained with fixed ratios of 4:1, 3:2, 2:3, and 1:4.

Video Microscopy. {#si11}
-----------------

Imaging was performed using a Nikon Eclipse TI-E inverted microscope through a Plan Apo λ 40× 0.95 N.A. dry objective (Nikon). For the bright field imaging, a halogen lamp with red filter was used as the light source. Time-lapse videos were recorded on a Grasshopper3 GS3-U3-23S6M-C camera (Point Gray Research) at four frames per second. For live-cell imaging, highly synchronous *P. falciparum* 3D7 late-stage schizonts were purified using a magnetic column (Miltenyi Biotec). After purification, *P. falciparum* cultures were resuspended at 4% hematocrit and diluted to 0.2% in complete medium to provide an optimal cell density and then incubated at 37 °C to allow for recovery. We mixed 25 μL of volume of this mixture with 25 μL of invasion inhibitory antibodies and placed it in a Secure-Seal hybridization chamber (Sigma-Aldrich) mounted on a glass slide. All live-cell experiments were performed in a homebuilt environmental chamber at 37 °C with a humidified gas supply (96% N~2~, 1% O~2~, and 3% CO~2~). A custom MATLAB program was employed to perform image recording and statistical analysis.
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